🔎 Trials Near Me

Home › Ulcerative Colitis › Ohio › Columbus

Ulcerative Colitis clinical trials in Columbus, OH

5 studies for Ulcerative Colitis are looking for participants at sites in and around Columbus (within about 30 miles). Open a study to see who can join and how to contact the study team.

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

RecruitingPhase 1
  • Ohio State University Comprehensive Cancer Center, Columbus
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

RecruitingPhase 2
  • Ohio State University, Hilliard · 10 mi away
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07415044

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

RecruitingPhase 4
  • Ohio Gastroenterology group, Inc., Columbus
Ages 18 to 65 · All sexes · Updated Sep 21, 2026 · NCT06095128

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

RecruitingPhase 3
  • Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
  • OSU Wexner Medical Center - Site Number: 8400077, Columbus
Ages 16 to 80 · All sexes · Updated Sep 15, 2026 · NCT07185009

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

RecruitingPhase 3
  • Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
  • OSU Wexner Medical Center - Site Number: 8400077, Columbus
Ages 16 to 80 · All sexes · Updated Aug 20, 2026 · NCT07184996

About Ulcerative Colitis

Ulcerative Colitis (UC) can cause long-lasting swelling and ulcers in the large intestine. It is a type of inflammatory bowel disease. Find out more.

More about Ulcerative Colitis on MedlinePlus

Ulcerative Colitis trials in other cities

Other studies in Columbus

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.